Coherus Biosciences | CHRS - Selling And Administration Expenses


Coherus Biosciences reported $15M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 190.54M 6.1M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.68B 40M Sep/2026
Baxter International USD 730M 5M Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 3.12B 305M Sep/2026
Fujifilm JPY 234.18B 4.23B Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Merck USD 2.86B 25M Sep/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Pacira USD 950.8M 858.99M Sep/2026
Perrigo USD 271.7M 3.01B Sep/2026
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Teva Pharmaceutical Industries USD 1.01B 27M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026
Xencor USD 71.93M 5.61M Sep/2026
Zoetis USD 582M 10M Sep/2026